濮阳东方妇科医院在什么地方(濮阳东方看妇科评价很好) (今日更新中)

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

UNITED NATIONS, Nov. 1 (Xinhua) -- China on Tuesday urged the International Atomic Energy Agency (IAEA) to further strengthen its leading role in enhancing global nuclear safety and promoting relevant international cooperation.Wang Min, Chinese deputy representative to the United Nations, made the remarks at an open meeting of the 66th session of UN General Assembly on the IAEA report.IAEA shoulders important responsibilities in promoting peaceful uses of nuclear energy and preventing nuclear proliferation, Wang said, adding that it needs to further summarize experiences and lessons of the Fukushima nuclear accident, assisting member states to enhance nuclear safety and emergency response capabilities.Wang urged the IAEA to "increase technical assistance to developing countries, improve newcomer's national nuclear infrastructure and promote the safe, secure and sustainable development of nuclear energy."The IAEA was also asked to strengthen nuclear safeguards regime, effectively prevent nuclear proliferation, and maintain an objective and impartial stand on sensitive and hot nuclear issues.China has always adhered to the principle of "safety first", he said. "China has established a rather comprehensive legal and standards system on nuclear safety, put in place an independent and effective supervision and regulatory framework, set up a comprehensive emergency response mechanism, and keep a good safety record in general."China has decided to contribute 200,000 U.S. dollars to the Nuclear Security Fund of the IAEA for the purpose of enhancing nuclear security capability of the Asia-Pacific Region, Wang added.

HONG KONG, Oct. 13 (Xinhua) -- Computer and electronic device maker Lenovo, listed in both Hong Kong and New York, has replaced Dell to become the world's second largest personal computer company, Lenovo said Thursday.Lenovo made the remarks in a statement, citing figures released by International Data Corporation (IDC), a global provider of business intelligence for the consumer technology market.Following five quarters as the fastest-growing PC maker among the world's top vendors, the preliminary IDC data reported that Lenovo has achieved record market share of around 13.7 percent and record quarterly shipment volume of some 12.6 million units.Lenovo CEO Yang Yuanqing said his company had surpassed two competitors to capture the No. 2 spot in worldwide PCs in just two quarters and it was the highest rank that Lenovo has achieved in worldwide PC sales.Given current competitive environment, the new achievement positioned Lenovo as a strong challenger to ultimately become the global market leader, Yang said in the statement."We are growing in the enterprise and the consumer space. And our customers know we are fully committed to the PC market for the long term," he said.At the same time, the Chinese multinational would continue investing in innovative products that would help drive the convergence of technologies and services across all four screens -- smart phones, tablets, PCs and smart TV, Yang said."We must deliver a great user experience across all platforms to achieve our goal and become the leading personal technology company in the world."Lenovo is a personal technology company and a global Fortune 500 company with annual sales worth 21 billion U.S. dollars. It serves customers in more than 160 countries and regions.

来源：资阳报